Inclusion Criteria:  Voluntarily sign the informed consent form; 18-75 years old; Women in any menstrual state, premenopausal or perimenopausal patients need to receive luteinizing hormone releasing hormone(LHRH) analogue; Eastern Cooperative Oncology Group (ECOG) score [0-1] points; The expected survival period is ≥12 weeks; The diagnosis of invasive carcinoma by histology or cytology; Estrogen receptor (ER) positive (defined as >1% nuclear ER staining); HER2 negative (defined as IHC 0 or 1+, or HER2(2+) with HER2 FISH detection no amplification); Inoperable or recurrent/metastatic breast cancer patients with aromatase inhibitor treatment failure; In the state of disease progression before enrollment; There are FGFR mutations, which meets any of the following: ①Immunohistochemical method: any subtype of FGFR1/2/3/4 is positive; ② Gene detection results of tissue/blood sample shows that any subtype of FGFR1/2/3/4 has functional variation such as amplification, activating mutation or fusion; Measurable disease according to RECIST version 1.1 or only bone metastasis; Adequate hematological, hepatic function; Doppler ultrasound: left ventricular ejection fraction (LVEF) ≥50%.  Exclusion Criteria:  Have used Fulvestrant or its analogues; History of other primary malignancy; Allergic to the ingredients of Anlotinib Hydrochloride Capsules; Previously received targeted drug therapy for FGFR; Received chemotherapy within 4 weeks before enrollment; Received endocrine therapy within 2 weeks before enrollment; Patients with currently symptomatic brain or meningeal metastasis; Concomitant diseases/conditions that is not controllable, and any other major illness that, in the investigator's judgment, will substantially increase the risk associated with the patient's participation in this study; Patients who cannot accept drugs orally; Any other situation that the investigator judges cannot be enrolled in the study.